Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 7 5 versus EVEKEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 7 5 versus EVEKEO.
ADDERALL 7.5 vs EVEKEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
None Documented
None Documented
The terminal elimination half-life of amphetamine is approximately 10-13 hours in adults, but can vary based on urinary pH (alkaline urine prolongs half-life up to 20 hours; acidic urine reduces it to 7-8 hours). In children, half-life is slightly shorter (6-8 hours). Clinical context: Steady-state is achieved within 2-3 days.
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites (including deaminated and hydroxylated products). Fecal excretion is negligible (<5%).
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Category C
Category C
CNS Stimulant
CNS Stimulant